| Pulmonary arterial hypertension
Adempass vs Uptravi
Side-by-side clinical, coverage, and cost comparison for pulmonary arterial hypertension.Deep comparison between: Adempas vs Uptravi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsUptravi has a higher rate of injection site reactions vs Adempas based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Uptravi but not Adempas, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Adempas
Uptravi
At A Glance
Oral
Three times daily
Soluble guanylate cyclase (sGC) stimulator
Oral / IV infusion
Twice daily
Prostacyclin receptor agonist
Indications
- Chronic thromboembolic pulmonary hypertension
- Pulmonary arterial hypertension
- Pulmonary arterial hypertension
Dosing
Chronic thromboembolic pulmonary hypertension, Pulmonary arterial hypertension Start at 1 mg three times a day (or 0.5 mg if hypotension risk); increase by 0.5 mg no sooner than every 2 weeks as tolerated, to a maximum of 2.5 mg three times a day.
Pulmonary arterial hypertension Starting dose 200 mcg orally twice daily; increase by 200 mcg twice daily at weekly intervals to the highest tolerated dose up to 1600 mcg twice daily. For moderate hepatic impairment (Child-Pugh class B), start at 200 mcg once daily and increase by 200 mcg once daily at weekly intervals. When co-administered with a moderate CYP2C8 inhibitor, reduce dosing to once daily. IV infusion (80-minute) is dosed twice daily at the corresponding tablet dose for patients temporarily unable to take oral therapy.
Contraindications
- Pregnancy
- Concomitant use of nitrates or nitric oxide donors in any form
- Concomitant use of PDE-5 inhibitors (sildenafil, tadalafil, or vardenafil) or nonspecific PDE inhibitors (dipyridamole or theophylline)
- Concomitant use of other soluble guanylate cyclase (sGC) stimulators
- Pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP)
- Hypersensitivity to selexipag or any excipient
- Concomitant use of strong CYP2C8 inhibitors (e.g., gemfibrozil)
Adverse Reactions
Most common (>=3%) Headache, dyspepsia and gastritis, dizziness, nausea, diarrhea, hypotension, vomiting, anemia, gastroesophageal reflux disease, constipation
Serious Embryo-fetal toxicity, hypotension, bleeding
Most common (>=3%) Headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in extremity, flushing, arthralgia, rash, anemia, decreased appetite
Postmarketing Symptomatic hypotension
Pharmacology
Riociguat is a soluble guanylate cyclase (sGC) stimulator with a dual mode of action: it sensitizes sGC to endogenous nitric oxide (NO) by stabilizing the NO-sGC binding, and directly stimulates sGC via a separate binding site independently of NO, increasing cGMP generation and leading to vasodilation.
Selexipag is a prostacyclin receptor (IP receptor) agonist structurally distinct from prostacyclin; it is hydrolyzed by carboxylesterase 1 to an active metabolite approximately 37-fold more potent, selective for the IP receptor over other prostanoid receptors (EP1-4, DP, FP, and TP).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Adempas
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Uptravi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (10/12)
UnitedHealthcare
Adempas
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (6/8)
Uptravi
- Covered on 4 commercial plans
- PA (4/8) · Step Therapy (4/8) · Qty limit (1/8)
Humana
Adempas
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
Uptravi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAdempas Co-pay Assistance Program
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/fillfill
Janssen CarePath Oral PAH Savings Program: UptraviCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AdempasView full Adempas profile
UptraviView full Uptravi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.